OsmanKostekMD· @OncologyMarwarD · X·· 3 天前评分70
正文 · 原文
🚨 #ESMO26 | CLARITY-Gastric01 Phase III
Sonesitatug vedotin in CLDN18.2+ gastric/GEJ cancer:
✅ 3L+ OS: 10 vs 5 mo (HR 0.47)
✅ ITT OS: 10.6 vs 6.4 mo
✅ ORR: 23.3% vs 13.8%
⚠️ ITT PFS not significant (p=0.053)
🎯 Promising new ADC in gastric cancer!
#GastricCancer #ADC
11 浏览 · 0 赞 · 0 转发 · 0 回复
来源：OsmanKostekMD · x.com